BusinessPhoto: Hindu BusinessAlembic Pharma Q2 Net Profit Rises 81% to ₹335 Crore
Alembic Pharmaceuticals reported an 81% year-on-year increase in consolidated net profit to ₹335 crore for the September quarter, driven by a 36% rise in revenue to ₹2,603 crore. The company expanded its collaboration with DifGen Pharmaceuticals to strengthen its U.S. market focus. Shares rose nearly 13% to ₹907.20 on the BSE. MD Pranav Amin highlighted strong U.S. volume growth and new launches.
Hindu Business··Hyderabad


